Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

Antitumor effects were noted in a heavily pretreated patient with CD19-negative myeloma who received CD19-specific chimeric antigen receptor T cells. The mechanism of the antitumor effects is unclear. Transduction of autologous T cells to express CD19-specific chimeric antigen receptors is a promisi...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 373; no. 11; pp. 1040 - 1047
Main Authors Garfall, Alfred L, Maus, Marcela V, Hwang, Wei-Ting, Lacey, Simon F, Mahnke, Yolanda D, Melenhorst, J. Joseph, Zheng, Zhaohui, Vogl, Dan T, Cohen, Adam D, Weiss, Brendan M, Dengel, Karen, Kerr, Naseem D.S, Bagg, Adam, Levine, Bruce L, June, Carl H, Stadtmauer, Edward A
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 10.09.2015
SeriesBrief Report
Subjects
Adult
Antigens
Antigens, CD19 - metabolism
Autografts
Bone Marrow - immunology
Bone Marrow - pathology
CD19 antigen
Cells
Chemotherapy
Chimeric antigen receptors
Female
Humans
Immunotherapy
Lymphocytes T
Melphalan
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - immunology
Multiple Myeloma - pathology
Patients
Plasma cells
Receptors, Antigen, T-Cell - therapeutic use
Remission Induction
Stem cell transplantation
Transplantation, Autologous
Urine
Online AccessGet full text

Cover

More Information
Summary:Antitumor effects were noted in a heavily pretreated patient with CD19-negative myeloma who received CD19-specific chimeric antigen receptor T cells. The mechanism of the antitumor effects is unclear. Transduction of autologous T cells to express CD19-specific chimeric antigen receptors is a promising immunotherapeutic approach for the treatment of B-cell cancers. 1 We previously reported sustained regression of refractory chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia 2 – 5 after infusion of CTL019 cells, which consist of autologous T cells expressing a CD3-zeta/CD137–based anti-CD19 chimeric antigen receptor from a lentiviral vector. Multiple myeloma is a B-lineage cancer that is reported to express CD19 infrequently 6 ; hence, CD19 is not generally considered a valid immunotherapeutic target in multiple myeloma. Several reports, however, have suggested that a minor component of the multiple myeloma . . .
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Report-3
ObjectType-Case Study-4
Drs. Garfall and Maus contributed equally to this article.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1504542